Evidence map›Paper›PMID 15540987›Full record

ArticleThe Biochemical journal2005

Lung Krüppel-like factor (LKLF) is a transcriptional activator of the cytosolic phospholipase A2 alpha promoter.

Marilee J Wick, Stacy Blaine, Vicki Van Putten, Milene Saavedra, Raphael A Nemenoff

Open access · greenAbstract read
In one paragraph

Article in The Biochemical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marilee J WickDepartment of Medicine, University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262, USA.
Stacy Blaine
Vicki Van Putten
Milene Saavedra
Raphael A Nemenoff
University of Colorado Health · US

Funding

Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8M
Preroxisome Proliferator-Activated Receptors in lung CancerR01CA108610 · NCI · UNIVERSITY OF COLORADO DENVER · PI NEMENOFF, RAPHAEL A. · 2004 to 2015
$2.9M
Role of cPLA2 in Lung Cancer: Microenvironment vs Tumor CellsR01CA103618 · NCI · UNIVERSITY OF COLORADO DENVER · PI NEMENOFF, RAPHAEL A. · 2003 to 2010
$1.9M
NCI NIH HHS CA103618NCI NIH HHS CA108610NCI NIH HHS CA58187NCI NIH HHS P50 CA058187NCI NIH HHS R01 CA103618NCI NIH HHS R01 CA108610
6 · The paper itself

Abstract

Increased expression of cPLA2 (cytosolic phospholipase A2) has been shown to be the cause of tumorigenesis of NSCLC (non-small-cell lung cancer). Our laboratory has previously demonstrated that oncogenic forms of Ras increase transcription of cPLA2 in normal lung epithelial cells and NSCLC lines through activation of the ERK (extracellular-signal-regulated kinase) and JNK (c-Jun N-terminal kinase) MAPK (mitogen-activated protein kinase) family. We have also defined a minimal region of the cPLA2 promoter that is critical for this induction. To identify potential transcription factors that bind to this region and regulate expression, a yeast one-hybrid screen was performed with a rat lung cDNA library. Multiple members of the Krüppel family were identified, with LKLF (lung Krüppel-like factor) being isolated a number of times. Overexpression of LKLF in lung epithelial cells or Drosophila SL-2 cells increased cPLA2 promoter activity. Conversely, expression of a dominant negative form of LKLF inhibited induction of cPLA2 promoter activity by oncogenic Ras in normal lung epithelial cells and NSCLC. By electrophoretic mobility-shift assay analysis, it was found that LKLF bound to a GC-rich region of the cPLA2 promoter located between -37 and -30 upstream from the transcription start site. Expression of siRNA (small interfering RNA) directed against LKLF inhibited basal expression of cPLA2 in lung epithelial cells and blocked induction by H-Ras. In NSCLC, siRNA against LKLF co-operated with siRNA against Sp1 (stimulatory protein 1) to inhibit cPLA2 promoter activity. Finally, recombinant LKLF was a substrate for ERKs. These results indicate that LKLF is an important regulator of cPLA2 expression and participates in the induction of this protein, which is critical for increased eicosanoid production associated with lung tumorigenesis.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungCell LineCell Line, TumorCytosolDrosophilaElectrophoretic Mobility Shift AssayEnzyme InductionEpithelial CellsGroup IV Phospholipases A2HumansKruppel-Like Transcription FactorsLungLung NeoplasmsPhospholipases APhospholipases A2Group IV Phospholipases A2KLF2 protein, humanKruppel-Like Transcription FactorsPhospholipases APhospholipases A2RNA, Small InterferingTrans-Activators

Identifiers

PMID15540987
PMCPMC1134952
OpenAlexW2031241049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.